Other (Income) Expense, Net (Details Textuals) In Millions	1 Months Ended	3 Months Ended			9 Months Ended
	Jan. 31, 2010	Sep. 30, 2011 USD ($)	Jun. 30, 2011 USD ($)	Sep. 30, 2010 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2010 USD ($)
Other (income) expense, net
Interest income		$ (45)		$ (23)	$ (137)	$ (57)
Interest expense		189		173	557	539
Exchange losses		59		8	102	84
Other, net		(137)		950	287	429
Other (income) expense, net		66		1,108	809	995
Other Income Expense Net (Textuals) [Abstract]
Gain on the disposition of the Company's interest in the JJMCP joint venture		136			136
Gain on AstraZeneca asset option exercise						443
Litigation losses				950	500	950
Gain on sale of manufacturing facilities and related assets					127
Recognition of income from disputed royalties						102
Interest paid					261	442
Exchange losses due to Venezuelan currency devaluation						80
Exchange rate prior to currency devaluation by Venezuelan government	2.15
Essentials exchange rate	2.60
Nonessentials exchange rate	4.30
Cash received on terminated interest rate swaps		$ 113	$ 175		$ 288